Advertisement

Topics

Peloton Therapeutics Completes $22.2 Million Private Financing

08:00 EDT 14 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Optional tranche of its Series D financing round brings total funding to $74.6 million Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies...

Other Sources for this Article

Peloton Contact:
Michael F. Haller, Ph.D.
Chief Business Officer
+1 972-629-4100
or
Media Contact:
Sam Brown Inc.
Mike Beyer, +1 312-961-2502
mikebeyer@sambrown.com

NEXT ARTICLE

More From BioPortfolio on "Peloton Therapeutics Completes $22.2 Million Private Financing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...